The Goldman Sachs Group Cuts Chemours (NYSE:CC) Price Target to $21.00

Chemours (NYSE:CC - Get Free Report) had its target price cut by The Goldman Sachs Group from $24.00 to $21.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a "neutral" rating on the specialty chemicals company's stock. The Goldman Sachs Group's price target indicates a potential upside of 11.35% from the company's current price.

CC has been the topic of a number of other reports. Morgan Stanley decreased their price objective on Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 5th. Royal Bank of Canada reissued an "outperform" rating and issued a $25.00 target price on shares of Chemours in a research note on Thursday, December 12th. BMO Capital Markets lifted their target price on Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, October 7th. Finally, Barclays boosted their target price on Chemours from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $24.13.

Chemours Stock Up 11.4 %

Shares of NYSE:CC traded up $1.93 during trading on Tuesday, hitting $18.86. The company's stock had a trading volume of 3,290,020 shares, compared to its average volume of 1,824,955. Chemours has a fifty-two week low of $15.10 and a fifty-two week high of $32.48. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The company has a market capitalization of $2.82 billion, a PE ratio of 37.72 and a beta of 1.83. The stock's 50-day moving average price is $19.28 and its two-hundred day moving average price is $20.00.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. Chemours's revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. As a group, sell-side analysts expect that Chemours will post 1.35 EPS for the current year.

Insider Buying and Selling

In other news, SVP Alvenia Scarborough sold 7,500 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company's stock, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.47% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Chemours

Several hedge funds have recently bought and sold shares of CC. KBC Group NV increased its stake in Chemours by 19.5% during the 3rd quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock valued at $91,000 after purchasing an additional 728 shares in the last quarter. Blue Trust Inc. increased its position in shares of Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after buying an additional 731 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 765 shares in the last quarter. Arizona State Retirement System raised its stake in Chemours by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 41,657 shares of the specialty chemicals company's stock valued at $940,000 after purchasing an additional 863 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in Chemours by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company's stock valued at $349,000 after acquiring an additional 1,175 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.